| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
– Focus development efforts on tagmokitug/toripalimab as a potential best-in-disease treatment for esophageal cancer with plans for expedited development – |
| 29 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
-1L ESCC confirmed ORR of 75% irrespective of PD-L1 status, confirmed ORR of 100% for PD-L1- positive, in evaluable patients- |
| 28 Aug 2026 |
8-K: Other Events
Coherus Oncology, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: |
| 17 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of August 17, 2026, is entered into by and between Coherus Oncology, Inc., a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC, a New York limited li... |
| 17 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a... |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – |
| 15 Jun 2026 |
8-K: Changes in Registrant's Certifying Accountant
We have read Item 4.01 of Form 8-K dated June 12, 2026, of Coherus Oncology, Inc. and are in agreement with the statements contained in the first, second, third and fourth paragraphs on page 1 therein. We have no basis to agree or disagr... |
| 01 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Coherus Oncology, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on May 27, 2026 virtually via the Internet. The Annual Meeting on May 27, 2026 was partially adjourned to Friday, May 29, 2026 sol... |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition
– Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, |
| 09 Mar 2026 |
8-K: Results of Operations and Financial Condition
– LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – |
| 17 Feb 2026 |
8-K: Other Events
Coherus Oncology, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), ... |
| 04 Feb 2026 |
8-K: Other Events
On February 4, 2026, Coherus Oncology, Inc. (the “Company”) announced a clinical supply agreement with Janssen Research & Development, LLC (“Janssen”), to evaluate tagmokitug (CHS-114), the Company’s investigational anti-CCR8 cytolytic m... |
| 23 Jan 2026 |
8-K: Other Events
Shares of Common Stock, $0.0001 par value per share, having an aggregate offering price of up to $64,880,054 |
| 13 Jan 2026 |
8-K: Results of Operations and Financial Condition
©2026 Coherus Oncology, Inc. Coherus Oncology Value Proposition Shareholder Value Creation Focused on Drugs, Data and Deals 1 DRUGS DATA DEALS Tagmokitug anti-CCR8 cytolytic antibody Casdozokitug IL-27 antagonist Commercial Stage Clinica... |
| 13 Nov 2025 |
8-K: Other Events
Certain matters discussed herein contain forward-looking statements. Any statements contained herein that are not statements of historical facts contained in this Annual Report on Form 10-K (“Form 10-K”) may be deemed to be forward-looki... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
– CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer – |
| 08 Sep 2025 |
8-K: Other Events
As previously disclosed, on June 30, 2025, Coherus Oncology, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying th... |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – |
| 03 Jul 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On June 30, 2025, Coherus Oncology, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the l... |
| 13 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Coherus Oncology, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) on June 11, 2025 virtually via the Internet. At the close of business on April 24, 2025, the record date, there were 115,922,573 s... |
Loading...